close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Quintiles to Add Jobs, Consolidate Atlanta Facilities

Global Central Laboratories, Clinical Development Services Moving To Marietta

RESEARCH TRIANGLE PARK, N.C., July 05, 2007 /PRNewswire/ -- Quintiles Transnational Corp. today announced plans to expand and consolidate its Global Central Laboratories in Smyrna, Ga., and its Clinical Development Services (CDS) office in Atlanta within a single structure in nearby Marietta, Ga.

The 201,366-square-foot, three-story structure in Marietta will more than double the combined space now occupied by Global Central Laboratories in Smyrna and CDS in Atlanta, allowing for the addition of about 400 jobs through 2011. Renovation of the structure is expected to begin the third quarter of 2007, with the first groups of employees scheduled to move during the second quarter of 2008.

"For our Global Central Laboratories, this is another expansion to accommodate the growth of our business, following the additions of labs in China and India and expansion of our lab in Scotland," said Dennis Gillings, CBE, Chairman and CEO of Quintiles Transnational. "The increasing demand for our CDS and laboratory services is driving the need to expand, and we're taking this opportunity to bring our Atlanta units together to improve coordination and efficiency for our customers."

Tom Wollman, Senior Vice President, Global Central Laboratories, said Quintiles wished to acknowledge the support of Cobb County, the Georgia Cancer Coalition, the Georgia Research Alliance and the Georgia Department of Economic Development for their support of this project. "With their help, Quintiles will be able to add up to 400 jobs in a rapidly expanding field. By more than doubling our capacity in the Atlanta area, we can stay ahead of the escalating demand for our services."

The value of the incentive package is estimated at $11 million and includes training, collaborations with the Georgia Research Alliance Technology Fund and access to the Georgia Cancer Coalition and its Distinguished Cancer Clinician and Scientist Program. The Cancer Coalition has a network of more than 100 oncologists ready to work with Quintiles on new clinical trials.

The project is being managed by Solution Property Group and renovation is being done by Purdum Construction of Kansas City, Mo. Quintiles is investing $19 million in the project.

About Quintiles Global Central Laboratories

Quintiles Laboratories owns a network of clinically harmonized facilities in the U.S., Europe, South Africa, China, India and Singapore, and has tightly controlled sub-contractor laboratories in Argentina and Brazil managed by Quintiles employees located in each of the facilities.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With about 18,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at www.quintiles.com.

CONTACT: Dick Jones, Media Relations, +1-919-998-2091, or, or Greg Connors, Investor Relations,+1-919-998-2000, or , both of Quintiles TransnationalCorp. media.info@quintiles.com invest@quintiles.com

Web site: http://www.quintiles.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...